Genome classifiers may aid prostate cancer risk stratification and treatment
1. In this systematic review, ten studies reported risk reclassification of prostate cancer with genome classifier testing, with wide variation ...
Tag: prostate cancer
Radiotherapy and abiraterone improve survival in low-volume metastatic castration-sensitive prostate cancer
1. Progression-free survival improved significantly in patients with low-volume disease who received abiraterone and radiotherapy. 2. The addition of radiotherapy ...
Stereotactic body radiotherapy is noninferior to hypofractionated radiotherapy for localized prostate cancer
1. In this randomized controlled trial, among patients with localized prostate cancer, five-fraction stereotactic body radiotherapy (SBRT) was found to ...
#VisualAbstract: Five-Fraction Stereotactic Body Radiotherapy was Noninferior to Control Radiotherapy in Biochemical or Clinical Failure in Localized Prostate Cancer
Click here to read this study in NEJM. ©2024 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced ...
MRI-informed biopsy recommendation reduces overdiagnosis in prostate cancer screening
1. In this randomized controlled trial of men aged 50 to 60, forgoing prostate biopsies in those with elevated PSA ...
#VisualAbstract 177Lu-PSMA-617 Prolonged Radiographic Progression-free Survival in Metastatic Prostate Cancer
Click here to read this study in the Lancet. ©2024 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced ...
Impact of different visceral metastatic sites on survival in metastatic prostate cancer patients
1. In a retrospective analysis of 59,875 patients with metastatic prostate cancer, varying prognoses were found primarily depending on the ...
bpMRI associated with higher false positive rate than PSA for prostate cancer screening
1. In this decision model analysis, biparametric MRI (bpMRI) testing led to an increased rate of overdiagnosis and false positives ...
Short-term androgen deprivation therapy does not improve survival in patients receiving postoperative radiotherapy for prostate cancer
1. There was no significant difference in metastasis-free survival between the ADT and non-ADT groups over 10 years. 2. Adverse ...
Novartis: ARV-766 is an androgen receptor degrader efficacious in treating metastatic prostate cancer
In patients with metastatic prostate cancer, ARV-766 treatment led to a greater than 50% reduction in Prostate-Specific antigen (PSA) in ...